Journal
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
Volume 9, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fcell.2021.661298
Keywords
peroxisome biogenesis disorder; Zellweger spectrum disorder; autophagy inhibitors; pexophagy; chloroquine; hydroxychloroquine; L-arginine; peroxisomal functions
Categories
Funding
- Hersenstichting [F 2012(1)-102]
- Marie Curie Initial Training Networks action [FP7-2012-PERFUME-316723]
- E-Rare-3 PERescue (ZonMW) [9003037605]
Ask authors/readers for more resources
This study investigated the potential use of autophagy inhibitors as a treatment option for PBD-ZSD patients carrying the PEX1-G843D mutation. However, the results showed that autophagy inhibitors did not improve peroxisomal functions, and in fact worsened metabolic functions and protein import in cells with the mutation. The study suggests that L-arginine remains a promising therapeutic compound for PBD-ZSD patients.
Peroxisome biogenesis disorders within the Zellweger spectrum (PBD-ZSDs) are most frequently associated with the c.2528G>A (p.G843D) mutation in the PEX1 gene (PEX1-G843D), which results in impaired import of peroxisomal matrix proteins and, consequently, defective peroxisomal functions. A recent study suggested that treatment with autophagy inhibitors, in particular hydroxychloroquine, would be a potential therapeutic option for PBD-ZSD patients carrying the PEX1-G843D mutation. Here, we studied whether autophagy inhibition by chloroquine, hydroxychloroquine and 3-methyladenine indeed can improve peroxisomal functions in four different cell types with the PEX1-G843D mutation, including primary patient cells. Furthermore, we studied whether autophagy inhibition may be the mechanism underlying the previously reported improvement of peroxisomal functions by L-arginine in PEX1-G843D cells. In contrast to L-arginine, we observed no improvement but a worsening of peroxisomal metabolic functions and peroxisomal matrix protein import by the autophagy inhibitors, while genetic knock-down of ATG5 and NBR1 in primary patient cells resulted in only a minimal improvement. Our results do not support the use of autophagy inhibitors as potential treatment for PBD-ZSD patients, whereas L-arginine remains a therapeutically promising compound.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available